UTHR trades 32.8% below Wall Street's consensus target of $650.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes UTHR achieves its forward estimates and maintains a stable P/E multiple of 18.8x. This scenario reflects the blended consensus of 30 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of September 24, 2026, United Therapeutics Corporation (UTHR) has a Wall Street consensus price target of $650.00, based on estimates from 30 covering analysts. With the stock currently trading at $489.42, this represents a potential upside of +32.8%. The company has a market capitalization of $20.77B.
Analyst price targets range from a low of $515.00 to a high of $735.00, representing a 34% spread in expectations. The median target of $700.00 differs from the mean, suggesting potential outlier estimates.
The current analyst consensus rating is Buy, with 17 analysts rating the stock as a Buy or Strong Buy,12 rating it Hold, and 1 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, UTHR trades at a trailing P/E of 17.6x and forward P/E of 18.8x. The forward PEG ratio of 0.97 suggests the stock may be undervalued relative to its growth. Analysts expect EPS to grow -8.9% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $732.49, with bear and bull scenarios of $461.47 and $965.13 respectively. Model confidence stands at 46/100, suggesting limited visibility into future performance.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 IDYAIDEAYA Biosciences, Inc. | $3.3B | $37.46 | $57.00 | +52.2% | Buy | — | 26 |
 RAREUltragenyx Pharmaceutical Inc. | $1.5B | $14.88 | $25.83 | +73.6% | Buy | — | 33 |
 ACADACADIA Pharmaceuticals Inc. | $4.4B | $25.43 | $33.83 | +33.0% | Buy | 41.1x | 37 |
 PTGXProtagonist Therapeutics, Inc. | $8.9B | $138.70 | $176.29 | +27.1% | Buy | 29.7x | 26 |
 INVAInnoviva, Inc. | $1.5B | $20.24 | $38.00 | +87.7% | Buy | 8.2x | 10 |
 HALOHalozyme Therapeutics, Inc. | $13.3B | $112.44 | $103.00 | -8.4% | Buy | 13.4x | 27 |
 MNKDMannKind Corporation | $1.1B | $3.34 | $9.00 | +169.5% | Buy | — | 20 |
 LNTHLantheus Holdings, Inc. | $6.5B | $99.97 | $104.48 | +4.5% | Buy | 18.5x | 19 |
 INSMInsmed Incorporated | $25.7B | $118.34 | $196.93 | +66.4% | Buy | — | 35 |
 LGNDLigand Pharmaceuticals Incorporated | $6.0B | $298.41 | $338.50 | +13.4% | Buy | 32.0x | 18 |
Quick answers to the most common questions about buying UTHR stock.
The consensus Wall Street price target for UTHR is $650, representing 32.8% upside from the current price of $489.42. With 30 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
UTHR has a consensus rating of "Buy" based on 30 Wall Street analysts. The rating breakdown is predominantly bullish, with 17 Buy/Strong Buy ratings. The consensus 12-month price target of $650 implies 32.8% upside from current levels.
With a forward P/E of 18.7597x, UTHR trades at a relatively low valuation. The consensus target of $650 implies 32.8% appreciation, suggesting meaningful undervaluation.
The most bullish Wall Street analyst has a price target of $735 for UTHR, while the most conservative target is $515. The consensus of $650 represents the median expectation. Our quantitative valuation model projects a bull case target of $965 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
UTHR is heavily covered by Wall Street, with 30 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 17 have Buy ratings, 12 recommend Hold, and 1 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month UTHR stock forecast based on 30 Wall Street analysts shows a consensus price target of $650, with estimates ranging from $515 (bear case) to $735 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $732, with bear/bull scenarios of $461/$965.
Our quantitative valuation model calculates UTHR's fair value at $732 (base case), with a bear case of $461 and bull case of $965. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 46/100.
UTHR trades at a forward P/E ratio of 18.8x based on next-twelve-months earnings estimates compared to a trailing P/E of 17.6x. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Wall Street analysts are very optimistic on UTHR, with a "Buy" consensus rating and $650 price target (32.8% upside). 17 of 30 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
UTHR analyst price targets range from $515 to $735, a 34% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $650 consensus represents the middle ground. Our model's $461-$965 range provides an independent fundamental perspective.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.